Drew Hill - ViewRay VP Devel

VRAYDelisted Stock  USD 0.04  0  5.67%   

Insider

Drew Hill is VP Devel of ViewRay
Phone440 703 3210
Webhttps://www.viewray.com

ViewRay Management Efficiency

The company has return on total asset (ROA) of (0.2529) % which means that it has lost $0.2529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0891) %, meaning that it created substantial loss on money invested by shareholders. ViewRay's management efficiency ratios could be used to measure how well ViewRay manages its routine affairs as well as how well it operates its assets and liabilities.
ViewRay currently holds 86.4 M in liabilities with Debt to Equity (D/E) ratio of 0.54, which is about average as compared to similar companies. ViewRay has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ViewRay's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Marna BorgstromArtivion
67
Julie GannonVivos Therapeutics
N/A
Thomas AckermanArtivion
66
George ParrInogen Inc
53
Shunichi KurodaBone Biologics Corp
N/A
Ehab EsmailOrthofix Medical
52
Blake GurfeinTivic Health Systems
40
Danielle WatsonHeart Test Laboratories
42
Veronica CaiTivic Health Systems
48
S MansbachAvanos Medical
N/A
Rajbir DenhoyEstablishment Labs Holdings
53
Joshua WellsArtivion
N/A
Andrew GreenArtivion
52
Ed JoyceAxogen Inc
N/A
Amy HortonArtivion
50
John LiuSight Sciences
N/A
Andre MarquetteNeuropace
N/A
Jon SalvesonArtivion
56
Bart BracyAnika Therapeutics
N/A
John DavisArtivion
59
Matthew PigeonInogen Inc
N/A
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio. Viewray operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 267 people. ViewRay (VRAY) is traded on NASDAQ Exchange in USA and employs 295 people.

Management Performance

ViewRay Leadership Team

Elected by the shareholders, the ViewRay's board of directors comprises two types of representatives: ViewRay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ViewRay. The board's role is to monitor ViewRay's management team and ensure that shareholders' interests are well served. ViewRay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ViewRay's outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert McCormack, Chief Officer
Robert Fuchs, Chief Officer
Zachary Stassen, Chief Officer
James Dempsey, Chief Scientific Officer, Director
Martin MD, Chief Officer
JD Ziegler, Chief Officer
Karen Hackstaff, VP Marketing
Scott Drake, CEO Pres
Matt Harrison, Director Relations
Drew Hill, VP Devel

ViewRay Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ViewRay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in ViewRay Stock

If you are still planning to invest in ViewRay check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ViewRay's history and understand the potential risks before investing.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance